'Telaprevir' diaporamas de présentation

Management of Chronic Hepatitis C in 2013

709 views • 43 slides

Antivirals

Antivirals. Lect 7,8 Sadia Anjum. Targets for Anti-viral therapy. 1. viral attachment to cell and fusion (fusion inhibitors). 2. protein translation in infected cells (interferon). 3. protein processing (specific protease inhibitors). DNA synthetic enzymes (reverse transcriptase

640 views • 39 slides

Treatment Guidelines Update

Treatment Guidelines Update. Delta AETC Faculty Development Conference Gulfport, MS, 23 June 2012 Ronald D. Wilcox, MD. Welcome!. Adult treatment guidelines March 27, 2012. HIV and the Older Patient Antiretroviral Drug Cost Table (Appendix C). Case 1.

536 views • 34 slides

Hepatitis B, C, and Beyond

Hepatitis B, C, and Beyond. John Scott, MD, MSc Feb 20, 2007 Harborview Medical Center. HCV/HIV Coinfection. When? With what? What next?. Case #1. 45 yo W man w/ B2 HIV, CD4 count 390, HIV load 100,000 copies/ml HCV+, GT 1a, HCV RNA 3 million IU/ml ALT 67 U/L, normal synthetic function

513 views • 34 slides

469 views • 33 slides

uw welzijn verdient onze beste zorg

436 views • 31 slides

Antiviral Agents

Antiviral Agents . Introduction. Because viruses are obligate intracellular parasites, identification of safe and effective antiviral therapies is difficult. The best antiviral drugs inhibit a specific step in viral replication or pathogenesis.

874 views • 30 slides

Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine

440 views • 29 slides

Direct Acting Antivirals: What are they? What is their place in HCV management?

Direct Acting Antivirals: What are they? What is their place in HCV management? . Mark Sulkowski, MD Associate Professor of Medicine Johns Hopkins University School of Medicine . Limitations of PegIFN + Ribavirin (with or without protease inhibitors).

429 views • 28 slides

State of Hepatitis C in Ghana

State of Hepatitis C in Ghana. Dr. Fred Stephen Sarfo (MD, FWACP, PhD ) Dept Internal Medicine, KATH. HCV in Ghana. HCV in Africa. Karoney et al., 2013. HCV in West Africa. Karoney et al., 2013. Sero -prevalence of HCV in Ghana. PUBMED Search, 33 articles. Excluded 17 articles.

384 views • 25 slides

HCV Therapy: Direct Acting Antiviral Agents in Co-Infected Individuals

HCV Therapy: Direct Acting Antiviral Agents in Co-Infected Individuals . Curtis Cooper, MD, FRCPC Faculty of Medicine, Division of Infectious Diseases University of Ottawa. APRICOT (Dietrich et al.) 95 centers, 19 countries (Canada 33 patients) Academic based RIBAVIC ( Perrone et al.)

379 views • 24 slides

Drug Interactions with Directly Acting Antivirals for HCV

351 views • 21 slides

VIRTUAL MEDZONE

VIRTUAL MEDZONE. Your Resource for Hepatitis Related Innovative Medical Communication. Hepatitis Case Presentations. Alice Tseng Pharm. D., FCSHP, AAHIVP David Fletcher MD FRCPC. CASE 1. 55 yo WF, diagnosed with HIV/HCV (genotype 1) 06/2000 CD4 1350, VL 1441 ? LT non- progressor HCV:

334 views • 21 slides

Update on the HCV Antiviral Pipeline

Update on the HCV Antiviral Pipeline. Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With PegIFN /RBV. APRICOT HIV Positive Overall SVR: 40%. PRESCO

212 views • 14 slides

Gastrointestinal System (GI tract)

Gastrointestinal System (GI tract). Is a long tube that consists of the mouth, esophagus, stomach, small intestine, large intestine, rectum and anus Several organs empty into the GI tract. These include the liver, pancreas, and the gall bladder with the salivary glands

354 views • 14 slides

Investigational Agents for HCV: I Thought This Was Going To Get Easier

Investigational Agents for HCV: I Thought This Was Going To Get Easier. Susanna Naggie, MD Assistant Professor of Medicine Duke Clinical Research Institute Durham, NC. From S Naggie , MD, at Washington, DC: June 18, 2013, IAS-USA. HIV & HCV. 10 million people worldwide

202 views • 13 slides

CASE 3

239 views • 9 slides

260 views • 8 slides

Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216)

Phase 3. Treatment Experienced. Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216). Zeuzem S, et al. N Engl J Med. 2011;364:2417-28. Telaprevir for Treatment-Experienced HCV Genotype 1 REALIZE Study: Study Design.

200 views • 8 slides

BOCEPREVIR & TELAPREVIR

BOCEPREVIR & TELAPREVIR. CHRIS SU. http:// www.youtube.com / watch?v =R4ld4WRUxq0. FDA APPROVED May 2011. (Vertex, 375mg oral). (Merck, 200mg oral). Mechanism of action. HCV Virus enters -> + RNA (9.6 kb) read by host ribosomes

251 views • 6 slides